EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Genetic Technologies's Enterprise Value is $7.62 Mil.
Genetic Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.98 Mil. Therefore, Genetic Technologies's EV-to-FCF for today is -1.53.
The historical rank and industry rank for Genetic Technologies's EV-to-FCF or its related term are showing as below:
GENE'
s EV-to-FCF Range Over the Past 10 Years
Min: -9.29 Med: -2.21 Max: -0.1
Current: -1.66
During the past 13 years, the highest EV-to-FCF of Genetic Technologies was -0.10. The lowest was -9.29. And the median was -2.21.
GENE's EV-to-FCF is ranked worse than 100% of 103
companies
in the Medical Diagnostics & Research industry
Industry Median: 24.94
vs GENE: -1.66
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Genetic Technologies's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genetic Technologies's EV-to-FCF
For the Diagnostics & Research subindustry, Genetic Technologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Technologies's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Genetic Technologies's EV-to-FCF falls into.
Genetic Technologies's current Enterprise Value is $7.62 Mil.
Genetic Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Genetic Technologies's PE Ratio for today is calculated as:
Genetic Technologies's share price for today is $2.221.
Genetic Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.249.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Genetic Technologies EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Genetic Technologies's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Genetic Technologies (Genetic Technologies) Business Description
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GENE has been successfully added to your 